[Experience with XXXX in hormone-resistant metastatic @entity263 that is unresponsive to @entity1205 ].

@entity1 @entity137 @entity263 @entity2240 @entity1205
INTRODUCTION: systemic treatment options for @entity1 with @entity263 ( @entity263 ) that progress despite the use of @entity1205 are very limited. One of the options of compassionate use currently available is the use of @entity2240 . We present a joint preliminary experience with the use of @entity2240 in this clinical case. @entity1 AND METHODS: a series of eight cases is presented, which sets forth a prospective multicentre experience with @entity2240 in @entity1 with hormone-refractory metastatic and progressive @entity263 , previously treated with at least a regime of @entity1205 -based chemotherapy. Other alternative chemotherapy regimes had already been tried in some @entity1 . The primary objective of our study was the PSA response rate and our secondary objective was the progression-free period. We administered a dosage of 50mg/day for four-week cycles, followed by a two-week rest per cycle, until we reached a total of eight cycles or up to clinical progression or intolerable @entity137 . RESULTS: in four cases, the PSA dropped to below 50% of the baseline level at the beginning of the treatment, and five @entity1 presented some decrease in PSA. The progression-free time was 16.4 weeks. @entity137 arising from the treatment was moderate and manageable. CONCLUSIONS: despite the limits of this experience, we can say that @entity2240 appears to be an active and safe option in @entity1 with @entity263 that is resistant to chemotherapy with @entity1205 .
